KBR (NYSE:KBR) reported quarterly adjusted earnings of $0.69 per share which beat the analyst consensus estimate of $0.58 by 18.97 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.61 billion which missed the analyst consensus estimate of $1.64 billion by 1.95 percent. This is a 35.65 percent decrease over sales of $2.50 billion the same period last year.
Cassava Sciences Announces Closing Of $50M Registered Direct Offering; Shares Move Higher
Cassava Sciences, Inc. (NASDAQ:SAVA) (the "Company" or "Cassava Sciences"), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the closing of its previously
